Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and six months ended June 30, 2021
Business Overview: The Company is the world's leading provider of products and services for individuals with renal diseases, operating a vertically integrated business model that includes dialysis care services and the manufacturing of health care products. Operations are organized into four geographic segments: North America, EMEA, Asia-Pacific, and Latin America.
Key Financial Metrics (Six Months Ended June 30, 2021)
| Metric | 2021 (€ M) | 2020 (€ M) | Change |
|---|---|---|---|
| Total Revenue | 8,530 | 9,045 | (6%) |
| Operating Income | 898 | 1,211 | (26%) |
| Net Income (Shareholders) | 468 | 634 | (26%) |
| Basic EPS | €1.60 | €2.15 | (26%) |
| Operating Margin | 10.5% | 13.4% | -290 bps |
| Net Debt | 11,708 | 11,298 | 3.6% |
| Net Leverage Ratio | 3.1x | 2.7x | 0.4x |
| Free Cash Flow | 749 | 2,407 | (69%) |
Note: Revenue and profit declines were significantly impacted by foreign currency translation effects (-8% on revenue) and the absence of U.S. federal relief funding (CARES Act) in 2021 compared to 2020.
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased 6% (reported) but grew 2% at constant currency. The decline was driven by a negative currency impact (-8%) and lower reimbursement for calcimimetics, partially offset by organic growth (+1%) and acquisitions (+1%).
- Profitability Pressure: Operating income fell 26% (reported) or 20% at constant currency. Gross profit decreased 11% due to higher personnel expenses, increased supply costs, and the absence of CARES Act funding. SG&A expenses increased 1% (reported) or 8% (constant currency) due to COVID-19 impacts and prior-year gains on clinic sales that did not repeat.
- Segment Performance:
- North America: Revenue flat at constant currency; operating income down 19% (constant currency) due to higher costs and lack of government relief.
- EMEA: Revenue up 2% (constant currency); operating income down 14% (constant currency) due to unfavorable currency transaction effects and manufacturing costs.
- Asia-Pacific: Revenue up 11% (constant currency); operating income up 25% (constant currency) driven by recovery in elective procedures.
- Latin America: Revenue up 17% (constant currency); operating income down 49% (constant currency) due to higher bad debt and personnel costs.
- Cash Flow: Net cash provided by operating activities dropped to €1,129 M from €2,903 M, primarily due to the recoupment of advanced Medicare payments received in 2020 and timing of expense payments.
Guidance, Outlook, and Risks
- Reimbursement Environment: CMS proposed a 1.0% increase in the ESRD PPS base rate for CY 2022. The Company faces uncertainty regarding the ESRD Treatment Choices (ETC) model and voluntary Kidney Care First (KCF) models, which may impact future revenue and expenses.
- COVID-19 Impact: The pandemic resulted in a negative impact of €154 M on net income for the six months ended June 30, 2021, compared to a €10 M impact in the prior year, largely due to excess mortality and reduced government relief.
- Liquidity and Debt: On July 1, 2021, the Company entered into a new €2 billion sustainability-linked syndicated credit facility, replacing the Amended 2012 Credit Agreement. Available borrowing capacity increased to €2.4 billion. Net leverage ratio increased to 3.1x.
- Legal and Regulatory: The Company is subject to ongoing investigations and litigation, including matters related to the Foreign Corrupt Practices Act (FCPA), False Claims Act, and patent infringement disputes regarding Velphoro®. A non-prosecution agreement with the DOJ and SEC is scheduled to terminate in 2022.
Investor Verification Checklist
- Currency Sensitivity: Verify the impact of EUR/USD fluctuations on reported results, as 69% of revenue is generated in U.S. dollars.
- Government Relief Recoupment: Confirm the timing and magnitude of recoupments for advanced Medicare payments received in 2020, which significantly reduced 2021 operating cash flow.
- Reimbursement Rates: Monitor final CMS rules for CY 2022 ESRD PPS and the implementation of the ETC model, which could alter payment structures for home dialysis and transplants.
- Latin America Impairment: Review the status of goodwill and asset impairments in the Latin America segment, which previously drove significant non-cash charges.
- Legal Reserves: Assess the adequacy of reserves for ongoing litigation, particularly regarding the FCPA monitorship and False Claims Act investigations.